Literature DB >> 27134669

Coffee, caffeine and non-alcoholic fatty liver disease?

Oliver John Kennedy1, Paul Roderick2, Robin Poole2, Julie Parkes2.   

Abstract

Entities:  

Year:  2016        PMID： 27134669      PMCID： PMC4830107          DOI： 10.1177/1756283X16636765

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


× No keyword cloud information.
  7 in total

1.  Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery.

Authors:  Rodolphe Anty; Sophie Marjoux; Antonio Iannelli; Stéphanie Patouraux; Anne-Sophie Schneck; Stéphanie Bonnafous; Camille Gire; Anca Amzolini; Imed Ben-Amor; Marie-Christine Saint-Paul; Eugenia Mariné-Barjoan; Alexandre Pariente; Jean Gugenheim; Philippe Gual; Albert Tran
Journal:  J Hepatol       Date:  2012-07-20       Impact factor: 25.083

Review 2.  Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis.

Authors:  Huafeng Shen; Andrea C Rodriguez; Ashok Shiani; Seth Lipka; Ghulamullah Shahzad; Ambuj Kumar; Paul Mustacchia
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 3.  Impact of coffee on liver diseases: a systematic review.

Authors:  Sammy Saab; Divya Mallam; Gerald A Cox; Myron J Tong
Journal:  Liver Int       Date:  2013-09-15       Impact factor: 5.828

4.  Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.

Authors:  Kiran Bambha; Laura A Wilson; Aynur Unalp; Rohit Loomba; Brent A Neuschwander-Tetri; Elizabeth M Brunt; Nathan M Bass
Journal:  Liver Int       Date:  2013-11-24       Impact factor: 5.828

Review 5.  I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.

Authors:  Jordan J Feld; Élise G Lavoie; Michel Fausther; Jonathan A Dranoff
Journal:  F1000Res       Date:  2015-04-21

6.  Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway.

Authors:  He Wang; Wenjie Guan; Wanzhi Yang; Qi Wang; Han Zhao; Feng Yang; Xiongwen Lv; Jun Li
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

Review 7.  Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis.

Authors:  Ming Ding; Shilpa N Bhupathiraju; Mu Chen; Rob M van Dam; Frank B Hu
Journal:  Diabetes Care       Date:  2014-02       Impact factor: 19.112
  7 in total
  4 in total

Review 1.  Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application.

Authors:  Hang-Yu Li; Ren-You Gan; Ao Shang; Qian-Qian Mao; Quan-Cai Sun; Ding-Tao Wu; Fang Geng; Xiao-Qin He; Hua-Bin Li
Journal:  Oxid Med Cell Longev       Date:  2021-03-01       Impact factor: 6.543

2.  Non-alcoholic fatty liver disease--a chronic disease of the 21<sup>st</sup> century.

Authors:  Peter Metrakos; Tommy Nilsson
Journal:  J Biomed Res       Date:  2018-09-29

Review 3.  Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates.

Authors:  Noel Salvoza; Pablo J Giraudi; Claudio Tiribelli; Natalia Rosso
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

4.  All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study.

Authors:  Oliver J Kennedy; Jonathan A Fallowfield; Robin Poole; Peter C Hayes; Julie Parkes; Paul J Roderick
Journal:  BMC Public Health       Date:  2021-06-22       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.